Argos Therapeutics Inc (NASDAQ:ARGS)’s share price traded down 12.5% during trading on Tuesday . The stock traded as low as $0.15 and last traded at $0.14. 3,618,110 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 2,398,062 shares. The stock had previously closed at $0.16.

The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29.

An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new position in shares of Argos Therapeutics Inc (NASDAQ:ARGS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent reporting period. 18.35% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Argos Therapeutics (ARGS) Shares Down 12.5%” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.